LONDON--(BUSINESS WIRE)--Virion Biotherapeutics announced today the appointments of Vanessa King, PhD, as President & Chief Executive Officer and Isabel Najera, PhD, as Chief Scientific Officer.
PHILADELPHIA, Oct. 26, 2023 /PRNewswire/ -- Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, and its Joint Venture partner, Ocean ...
Providence, RI, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research ...
Virion Biotherapeutics announced Monday that Vanessa King and Isabel Najera have signed on as CEO and chief scientific officer, respectively. King has held a number of business development and ...
Researchers at Semmelweis University and the National Public Health Center in Hungary have conducted an imaging study showing that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the ...
This is a preview. Log in through your library . Abstract The virion host shutoff protein product of the U L 41 gene of herpes simplex virus 1 is an endoribonuclease that selectively degrades mRNAs ...
A team of scientists of the University of Chicago and the University of California San Diego has developed a coarse-grained (CG) model of the severe acute respiratory syndrome coronavirus 2 ...
Some of the ultrastructural morphology displayed by an Ebola virus virion is revealed in this undated handout colorized transmission electron micrograph (TEM) obtained by Reuters August 1, 2014.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback